Loading
Yanuki
KEYWORD TOPIC
Pancreatic Cancer mRNA Vaccine Shows Lasting Results in Early Trial | COVID mRNA Vaccines Boost Immunotherapy Effectiveness for Cancer Patients | Federal Cuts to mRNA Vaccine Development Impact Vermont | RFK Jr. Cancels Federal Funding for mRNA Vaccine Development: Experts Warn of Public Health Risks | RFK Jr. Halts $500M Funding for mRNA Vaccine Development, Prioritizes Alternative Strategies | Pancreatic Cancer mRNA Vaccine Shows Lasting Results in Early Trial | COVID mRNA Vaccines Boost Immunotherapy Effectiveness for Cancer Patients | Federal Cuts to mRNA Vaccine Development Impact Vermont | RFK Jr. Cancels Federal Funding for mRNA Vaccine Development: Experts Warn of Public Health Risks | RFK Jr. Halts $500M Funding for mRNA Vaccine Development, Prioritizes Alternative Strategies

Health / Cancer

Pancreatic Cancer mRNA Vaccine Shows Lasting Results in Early Trial

An early clinical trial has revealed promising long-term results for a personalized mRNA vaccine targeting pancreatic cancer. The study, led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center, followed patients for six year...

Pancreatic cancer mRNA vaccine shows lasting results in an early trial
Pancreatic Cancer mRNA Vaccine Shows Lasting Results in Early Trial Image via NBC News
TOPIC mrna vaccine

Health / Cancer

COVID mRNA Vaccines Boost Immunotherapy Effectiveness for Cancer Patients

A recent study indicates that mRNA COVID-19 vaccines can significantly enhance the effectiveness of immunotherapy in cancer patients, particularly those with lung cancer and melanoma. The research suggests a potential doubling of survival r...

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

Health / Vaccines

Federal Cuts to mRNA Vaccine Development Impact Vermont

Federal cuts to mRNA vaccine development are beginning to impact local manufacturers in Vermont, raising concerns about future pandemic preparedness and the long-term health of the mRNA industry.

Opinion | Jay Bhattacharya: Why the NIH is pivoting away from mRNA vaccines